Comparative Pharmacology
Head-to-head clinical analysis: BETIMOL versus NEBIVOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETIMOL versus NEBIVOLOL HYDROCHLORIDE.
BETIMOL vs NEBIVOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist with nitric oxide-mediated vasodilatory activity via stimulation of beta-3 receptors.
1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. If inadequate response, increase to 0.5% solution twice daily.
5 mg orally once daily. May be initiated at 2.5 mg in patients with renal impairment or those at risk of hypotension. Titrate at 2-week intervals up to 40 mg once daily.
None Documented
None Documented
2.5 to 5 hours (average 4 hours) in patients with normal renal function; may be prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life: 12-19 hours in extensive metabolizers; up to 30-50 hours in poor CYP2D6 metabolizers; clinically, once-daily dosing is effective due to pharmacodynamic half-life >40 hours.
Primarily renal (unchanged drug and metabolites). Approximately 60-80% of a dose is excreted renally as unchanged timolol, with the remainder as inactive metabolites. Biliary/fecal excretion accounts for less than 20%.
Approximately 38% renal, 48% fecal (unchanged drug and metabolites); extensive hepatic metabolism (CYP2D6) with glucuronidation; <1% excreted unchanged in urine.
Category C
Category A/B
Beta-Blocker
Beta-Blocker